Senectus Therapeutics

Senectus Therapeutics is a life sciences company focused on regenerative medicine and the global development and commercialization of cell and gene therapies. Its current public-facing business centers on Chondrochymal, an investigational bone marrow-derived mesenchymal stem cell therapy for knee osteoarthritis and cartilage regeneration. The company describes itself as clinical-stage and is supporting an ongoing Phase III trial in Taiwan while building regulatory and commercialization pathways across multiple jurisdictions. Public sources also indicate that an older UK entity named Senectus Therapeutics Limited previously operated in oncology drug discovery focused on cellular senescence and was dissolved in 2021, while the currently active Singapore-based business appears to be a distinct operating entity using the Senectus Therapeutics name.